The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

P+P Pöllath + Partners

POTSDAMER PLATZ 5, 10785 BERLIN, GERMANY
Tel:
Work +49 30 25 35 30
Email:
Web:
www.pplaw.com
Berlin, Frankfurt, Munich

Amos Veith

Tel:
Work +49 (30) 25353 124
Email:
P+P Pöllath + Partners

Work Department

Private Funds, Steuerrecht

Position

Amos Veith, LL.M. ist Partner bei P+P Pöllath + Partners. Er ist spezialisiert auf die steuerliche und rechtliche Beratung von institutionellen und privaten Investoren und Initiatoren im Bereich der Strukturierung von Private Equity, Mezzanine und Secondaries. Amos Veith ist in nationalen und internationalen Rankings als führender Berater für Private Funds gelistet.

Career

Bei P+P seit 2001, Studium der Rechtswissenschaften in Bonn, Köln und Aberdeen (LL.M. 1998)

Languages

Deutsch, Englisch

Member

Mitbegründer der "Hamburger Fondsgespräche"

Education

Zulassung als Rechtsanwalt 2001, LL.M. 1998


Deutschland: Bank- und Finanzrecht

Investmentfonds

Within: Investmentfonds

Bei P+P Pöllath + Partners schätzen Mandanten das 'sehr hohe Servicelevel', das auf 'kurzen Bearbeitungszeiten, einer verlässlichen Einhaltung vorgegebener Deadlines und auf einem ausgezeichneten Preis-Leistungsverhältnis' beruht. Außerdem zählt die 'Branchenkenntnis in den Bereichen Private Equity und M&A' zur besonderen Stärke des 'sorgfältigen und zielorientierten' Teams. Man berät Initiatoren und Investoren zu allen rechtlichen, steuerlichen und aufsichtsrechtlichen Aspekten von Private Equity-Fonds, deren alternativen Investmentfonds und weltweiten Fondsbeteiligungen, wobei dem Team die enge Verzahnung der Bereiche Fondsstrukturierung, Aufsichtsrecht und Steuerrecht zugutekommt. So beriet der 'proaktive' Amos Veith, der gemeinsam mit dem 'absoluten Marktkenner' Andreas Rodin die Praxis leitet und 'in den Bereichen PE- und VC-Fonds zu den führenden Namen Deutschlands zählt' und zudem 'sehr angenehm in der persönlichen Zusammenarbeit ist', den Private Equity-Investor AFINUM Management umfassend zu steuerlichen und rechtlichen Themen betreffend Fondsstrukturierung und Vertragsdokumentation sowie bei Verhandlungen mit in- und ausländischen Investoren. Im regulatorischen Bereich liegt der Beratungsschwerpunkt auf Themen mit Bezug auf MiFID II, EuVECA und die PRIIP-Verordnung, während man auch in der Beratung von Private Debt-, Venture Capital-, Corporate Venture Capital und Immobilienfonds sowie Infrastruktur- und Energiefonds erfahren ist, wie auch bei luxemburgischen Fondsstrukturen. Daneben ist man zunehmend im Management-Bereich tätig: hier betreut man institutionelle Investoren und deren Asset-Manager beim Aufbau von Plattformen zum Management alternativer Fondsinvestitionen. Uwe Bärenz und der Anfang 2018 in Berlin zum Partner ernannte Tarek Mardini sind weitere Mitglieder des Teams, dessen Mandantenportfolio Caplantic und Commodus Real Estate Capital einschließt.

[von unten nach oben]

Deutschland: Private Equity

Private Equity - Transaktionen

Within: Private Equity - Transaktionen

P+P Pöllath + Partners gilt insbesondere in den Bereichen Managementberatung, Managementbeteiligungsprogramme und Fondsstrukturierung als Top-Adresse und ist in der Transaktionsbegleitung im mittelgroßen Marktsegment erfahren. So beriet ein Team um Benedikt Hohaus das Management der NuCom Group beim Verkauf einer Minderheitenbeteiligung an den Private Equity-Investor General Atlantic und Ralf Bergjan betreute die von Equistone Partners Europe beratenen Fonds bei der Veräußerung der Mehrheitsbeteiligung an der OASE Gruppe an den amerikanischen Private Equity-Investor Argand Partners. Jens Hörmann beriet die deutsche Beteiligungsgesellschaft Odewald & Compagnie beim Verkauf der gesamten Beteiligung am Klinikverbund Oberberggruppe an Trilantic Europe und betreute Charleston und den dahinter stehenden Fonds EQT Infrastructure beim Erwerb der Christophorus-Gruppe. Daneben zählen unter anderem Andreas Rodin, Amos Veith, Uwe Bärenz und Matthias Bruse zu den empfohlenen Beratern. Letztgenannter begleitete Findos Investor beim Erwerb von CELLULAR. Christian Tönies ist 'extrem erfahren, pragmatisch und lösungsorientiert'. Counsel Tarek Mardini wurde im Januar 2018 zum Partner ernannt.

[von unten nach oben]


Back to index

Co-Publishing weltweit

Rechtsentwicklungen und Neuigkeiten der führenden Anwälte in verschiedenen Jurisdiktionen. Für Beitrüge schicken Sie bitte eine Anfrage per Email an
  • China Drug Registration Regulation - Public consultation on amendment closes - March 2014

    In February 2014, the China Food and Drug Administration (“CFDA”) invited second-round comments from the public regarding proposed amendments to the China Drug Registration Regulations (“DRR”). One of the proposed amendments touches upon patent protection for drugs in China.
  • Revised NDRC Measures for Approval and Filing of Outbound Investment Projects - April 2014

    The National Development and Reform Commission ( NDRC ) released a new set of Management Measures for Approval and Filing of Outbound Investment Projects ( 境外投资项目核准和备案管理办法) ( New Measures ) on 8 April 2014. The New Measures take effect on 8 May 2014 and will replace the Interim Management Measures for Approval of Outbound Investment Projects ( 境外投资项目核准暂行管理办法) ( Original Measures ) which have been in force since 9 October 2004.
  • Insurance Update - CIRC Issues Insurance M&A Measures: What are the impacts and applications?

    On 21 March 2014, CIRC issued the Administrative Measures on the Acquisition and Merger of Insurance Companies (the Insurance M&A Measures ) which will take effect from 1 June 2014. The Insurance M&A Measures apply to M&A activities whereby an insurance company is the target for a merger or acquisition. The target insurance company could be either a domestic or a foreign invested insurer. However, the Insurance M&A Measures will not apply to any equity investment by insurance companies in non-insurance companies in China or in overseas insurance companies.
  • China issues new rules to regulate medical devices - May 2014

    The Regulations on Supervision and Administration of Medical Devices (in Chinese《医疗器械监督管理条例》, State Council Order No. 650) (the Medical Device Regulations) were amended by China's State Council on 31 March 2014 and will come into effect on 1 June 2014. This is the first amendment in more than a decade since the Medical Device Regulations were first promulgated in 2000, even though the amendment was initiated eight years ago in 2006. The 2014 amendment unveils reforms on the regulatory regime for medical devices market in China from various aspects.
  • Hong Kong: The evolving role of independent non-executive directors - May 2014

     In a recent speech given by Mr. Carlson Tong, Chairman of the Securities and Futures Commission, Mr. Tong pointed out that companies can improve corporate governance by attaching higher importance to the role of their board of directors as an internal gatekeeper. Mr. Tong said that this can be done more easily by having effective independent non-executive directors (INEDs) on the board.
  • Walking a fine line in China:Distinguishing between legitimate commercial deals and commercial bribe

    China in the 21st century exemplifies an atmosphere of great opportunity and intense competition. Against this backdrop, it has become increasingly common for businesses to adopt a variety of practices in order to make their products and services competitive. Such practices may include paying middle-men to promote sales and giving incentives to buyers directly. However, whilst revenue spikes are undoubtedly welcome, businesses should bear in mind the potential backlash arising out of these commercial arrangements. The risk that such arrangements may not comply with anti-bribery and corruption laws and therefore cause business significant damage in the long term should not be underestimated.
  • Competition law developments in East Asia - May 2014

    Authorities in Hong Kong have taken further steps in their deliberate approach to enforcing the Competition Ordinance. A little over a year after it was appointed, the Competition Commission released a report in which it provides a brief introduction to the Ordinance as well as a roadmap leading to its full entry into force. The report also explains how the Commission will prioritise its enforcement activities, and identifies the guidelines, policies and compliance tools which it plans to release before the Ordinance is enforced. Currently only some of the institutional provisions of the Ordinance are effective, allowing the Commission and the Competition Tribunal to prepare for enforcement.
  • Rise of the private healthcare sector - July 2014

    As of 2013, China had 9,800 private hospitals, representing almost half of the total number of hospitals in the country 1 . However, private hospitals still severely lag behind their public peers due to low utilisation, talent shortages and incomplete social insurance coverage. As part of China's ongoing healthcare reform initiatives, the Chinese government has set a goal to increase the share of patients treated by private hospitals to 20% by the end of 2015 2 .
  • Walking a Tightrope in Singapore - July 2014

    The world has no borders and distance is negligible for the technologically savvy criminal. Individuals with illicit funds to launder or terrorist activities to finance can, with the latest technology, transfer high volumes of money around the globe almost instantaneously and seek to conceal the origin or the destination of the funds.
  • Indonesia banking bill: proposed restrictions on foreign investment - July 2014

    Indonesia's House of Representatives is currently considering a new draft banking bill (the Banking Bill ) which, if passed into law in its current form, will: